Cargando…

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials

Accurate assessment of LDL-C levels is important, as they are often used for treatment recommendations. For many years, plasma LDL-C levels were calculated using the Friedewald equation, but there are limitations to this method compared with direct measurement via beta-quantification (BQ). Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginsberg, Henry N., Rosenson, Robert S., Hovingh, G. Kees, Letierce, Alexia, Samuel, Rita, Poulouin, Yann, Cannon, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Patient-oriented and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953656/ https://www.ncbi.nlm.nih.gov/pubmed/34774485 http://dx.doi.org/10.1016/j.jlr.2021.100148

Ejemplares similares

Friedewald, Martin/Hopkins ou Sampson/NIH: Qual o Melhor Método para Estimar o LDL-Colesterol?
por: Cesena, Fernando
Publicado: (2022)

Assessing the Practical Differences in LDL-C Estimates Calculated by Friedewald, Martin/Hopkins, or NIH Equation 2: An Observation Cross-Sectional Study
por: Wang, Inga, et al.
Publicado: (2023)

Concordance of apolipoprotein B concentration with the Friedewald, Martin-Hopkins, and Sampson formulas for calculating LDL cholesterol
por: Briers, Pieter-Jan, et al.
Publicado: (2021)

Validation of Friedewald, Martin-Hopkins and Sampson low-density lipoprotein cholesterol equations
por: Ertürk Zararsız, Gözde, et al.
Publicado: (2022)

Comparison of measured LDL cholesterol with calculated LDL-cholesterol using the Friedewald and Martin-Hopkins formulae in diabetic adults at Charlotte Maxeke Johannesburg Academic Hospital/NHLS Laboratory
por: Dintshi, Mogomotsi, et al.
Publicado: (2022)

Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation
por: Singh, Gurpreet, et al.
Publicado: (2020)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
por: Henry, Robert R., et al.
Publicado: (2018)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012)

Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C
por: Hellstrand, S., et al.
Publicado: (2012)

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
por: Dandan, Mohamad, et al.
Publicado: (2023)

Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson’s, Martin’s and Friedewald’s equations
por: Vargas-Vázquez, Arsenio, et al.
Publicado: (2021)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
por: Vallejo‐Vaz, Antonio J., et al.
Publicado: (2018)

Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol
por: Fukuyama, Naoto, et al.
Publicado: (2008)

Intuitive Modification of the Friedewald Formula for Calculation of LDL-Cholesterol
por: Hong, Jinyoung, et al.
Publicado: (2023)

Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol
por: Reiber, Istvan, et al.
Publicado: (2020)

The direct correlation between oxidative stress and LDL-C levels in adults is maintained by the Friedewald and Martin equations, but the methylation levels in the MTHFR and ADRB3 genes differ
por: de Oliveira, Jéssica Vicky Bernardo, et al.
Publicado: (2020)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Friedewald’s equation for calculating LDL-cholesterol: Is it the time to say “Goodbye” and adopt direct LDL cholesterol methods?
por: Khan, Sikandar Hayat, et al.
Publicado: (2019)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
por: Leiter, L. A., et al.
Publicado: (2018)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Comparison of the effectiveness of Martin’s equation, Friedewald’s equation, and a Novel equation in low-density lipoprotein cholesterol estimation
por: Song, Youhyun, et al.
Publicado: (2021)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Friedewald formula may be used to calculate non-HDL-C from LDL-C and TG
por: Romaszko, Jerzy, et al.
Publicado: (2023)

RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017)

Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes
por: Connelly, Philip W., et al.
Publicado: (2009)

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity
por: Rubinow, Katya B., et al.
Publicado: (2012)

Plasma apolipoprotein O level increased in the patients with acute coronary syndrome
por: Yu, Bi-lian, et al.
Publicado: (2012)

Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects
por: Ooi, Esther M. M., et al.
Publicado: (2012)

Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
por: Shearer, Gregory C., et al.
Publicado: (2012)

Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis
por: Gaspar, Paulo, et al.
Publicado: (2014)

New insights regarding tissue Se and Hg interactions on oxidative stress from plasma IsoP and IsoF measures in the Canadian Inuit population
por: Alkazemi, Dalal, et al.
Publicado: (2013)

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
por: Meikle, Peter J., et al.
Publicado: (2015)

Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies(1)
por: Tsiantoulas, Dimitrios, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7qamlnaok4cu6rki9odsdj3e77